L9918
Anti- LRRK2 (C-terminal region)
~1.0 mg/mL, affinity isolated antibody, buffered aqueous solution
别名:
Anti-AURA17, Anti-Dardarin, Anti-Leucine-rich repeat protein kinase 2, Anti-PARK8, Anti-RIPK7, Anti-ROCO2
登录 查看组织和合同定价。
选择尺寸
关于此项目
NACRES:
NA.44
UNSPSC Code:
12352203
Conjugate:
unconjugated
Clone:
polyclonal
Application:
WB
Citations:
8
biological source
rabbit
conjugate
unconjugated
antibody form
affinity isolated antibody
antibody product type
primary antibodies
clone
polyclonal
form
buffered aqueous solution
mol wt
antigen ~240 kDa
species reactivity
rat, mouse, human
enhanced validation
recombinant expression
Learn more about Antibody Enhanced Validation
concentration
~1.0 mg/mL
technique(s)
western blot: 2-4 μg/mL using HEK-293T cells expressing human LRRK2, and using rat and mouse brain extracts (S2 fraction)
UniProt accession no.
shipped in
dry ice
storage temp.
−20°C
target post-translational modification
unmodified
Quality Level
Gene Information
human ... LRRK2(120892)
mouse ... Lrrk2(66725)
rat ... Lrrk2(300160)
相关类别
General description
Leucine-rich repeat protein kinase 2 (LRRK2) comprises multiple domains, including a leucine-rich repeat (LRR) domain, a Roc (Ras of complex proteins) GTPase domain followed by a C-terminal of ROC (COR) domain, a Ser/Thr kinase domain and a C-terminal Trp-Asp-40 (WD40) domain. The N-terminal region (?900 amino acids) contains ankyrin (ANK) repeats. The LRRK2 homologue LRRK1 shares domain structure similarity with LRRK2.
Application
Anti-LRRK2 (C-terminal region) antibody is suitable for use in western blot (2-4 μg/mL using HEK-293T cells expressing human LRRK2, and using S2 fractions of rat and mouse brain extracts).
Biochem/physiol Actions
Anti-LRRK2 (C-terminal region) antibody is specific for LRRK2 (approx. 240 kDa) in mice, rats and humans.
LRRK2 is a μLtimeric kinase that also functions as a GTPase. LRRK2 activates a calcium/calmodulin-dependent protein kinase kinase (CaMKK)-β/AMPK signaling pathway and subsequently mediates autophagy. Genetic alterations in LRRK2 cause late-onset Parkinson′s disease . Anti-LRRK2 (C-terminal region) antibody is specific for LRRK2 (approx. 240 kDa) in mice, rats and humans. Staining of the LRRK2 band by immunoblotting is specifically inhibited by the LRRK2 immunizing peptide.
LRRK2 mRNA is expressed throughout the brain predominantly within regions of the basal ganglia that are associated with Parkinson′s disease. The presence of multiple protein interaction domains suggests that in addition to its kinase and GTPase activities, LRRK2 may serve as a scaffold protein for the assembly of multiprotein signaling complex. R1441C mutation has been shown to disrupt GTPase activity. G2019S and R1441C, both associated with increased kinase activity.
Physical form
Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
未找到合适的产品？
试试我们的产品选型工具.
存储类别
10 - Combustible liquids
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, multi-purpose combination respirator cartridge (US)
法规信息
低风险生物材料
常规特殊物品
此项目有
Kinase activity of mutant LRRK2 manifests differently in hetero-dimeric vs. homo-dimeric complexes
Leandrou E, et al.
The Biochemical Journal, 476(3), 559-579 (2019)
The R1441C mutation of LRRK2 disrupts GTP hydrolysis
Lewis PA, et al.
Biochemical and biophysical research communications, 357(3), 668-671 (2007)
Expression and localization of Parkinson's disease-associated leucine-rich repeat kinase 2 in the mouse brain
Higashi S, et al.
Journal of Neurochemistry, 100(2), 368-381 (2007)
Crystal structure of the WD40 domain dimer of LRRK2
Zhang P, et al.
Proceedings of the National Academy of Sciences of the USA, 116(5), 1579-1584 (2019)
Patricia Gómez-Suaga et al.
Human molecular genetics, 21(3), 511-525 (2011-10-21)
Mutations in the leucine-rich repeat kinase-2 (LRRK2) gene cause late-onset Parkinson's disease, but its physiological function has remained largely unknown. Here we report that LRRK2 activates a calcium-dependent protein kinase kinase-β (CaMKK-β)/adenosine monophosphate (AMP)-activated protein kinase (AMPK) pathway which is
相关内容
Instructions
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持